Attached files

file filename
EX-99.1 - EXHIBIT 99.1 - Therapeutics Acquisition Corp.tm2024892d1_ex99-1.htm

 

 

 

UNITED STATES

 

SECURITIES AND EXCHANGE COMMISSION

 

Washington, D.C. 20549

 

 

FORM 8-K

 

CURRENT REPORT

 

 

PURSUANT TO SECTION 13 OR 15(D) OF THE

 

SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): July 16, 2020 (July 10, 2020)

 

THERAPEUTICS ACQUISITION CORP.

(Exact name of registrant as specified in its charter)

 

Delaware

(State or other jurisdiction of

incorporation)

 

001-39373 

(Commission File Number)

 

85-0800493

(I.R.S. Employer Identification No.)

 

200 Berkeley Street
18th Floor
Boston, MA

(Address of principal executive offices)

02116

(Zip Code)

 

(617) 778.2500

 

(Registrant’s telephone number, including area code)

 

Not Applicable

 

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

  

¨Pre-commencements communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

  

 

Title of each class

 

 

Trading Symbols

 

Name of each exchange on

 which registered

         

Class A common stock, par value $0.0001 per share

  TXAC   The Nasdaq Capital Market

 

x Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

¨ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  

 

 

 

 

 

 Item 8.01 Other Events

 

On July 10, 2020, Therapeutics Acquisition Corp. (the “Company”) consummated its initial public offering (“IPO”) of 13,570,000 shares of Class A common stock (the "Class A Common Stock"), including the issuance of 1,770,000 shares as a result of the underwriters' exercise in full of their over-allotment option. The Class A Common Stock was sold at a price of $10.00 per share, generating gross proceeds to the Company of $135,700,000.

 

On July 10, 2020, substantially concurrent with the consummation of the IPO, the Company completed the private sale (the “Private Placement”) of an aggregate of 471,400 shares of Class A common Stock (the “Private Placement Shares”) to Therapeutics Acquisition Holdings LLC  at a purchase price of $10.00 per Private Placement Share, generating gross proceeds to the Company of $4,714,000.

 

An audited balance sheet as of July 10, 2020 reflecting receipt of the proceeds upon consummation of the IPO and the Private Placement has been issued by the Company and is included as Exhibit 99.1 to this Current Report on Form 8-K.

 

Item 9.01 Financial Statements and Exhibits.

 

  (d) Exhibits

 


EXHIBIT INDEX

 

Exhibit
No.
  Description
99.1   Audited Balance Sheet as of July 10, 2020.

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

   
  Therapeutics Acquisition Corp.
   
Date: July 16, 2020 By: /s/ Matthew Hammond
  Name: Matthew Hammond
  Title: Chief Financial Officer